What an exciting year it has been for PQA! As we continue progress towards completion of our strategic plan, Blueprint PQA 2025, our team has been hard at work alongside our valued members to deliver meaningful improvements and drive positive change in quality medication use.
Chronic obstructive pulmonary disease (COPD) is a serious global health concern impacting millions of individuals. Despite being the third leading cause of mortality worldwide, COPD remains underdiagnosed and undertreated. Quality measures are a vital component of value-based payment models, but there are few COPD measures in current U.S. quality reporting programs, despite the established burden of COPD.
PQA offers a variety of student and professional programs, including experiential rotations, internships and fellowships. Each focuses on providing health care quality experience to diverse individuals from diverse disciplines. PQA is now accepting applications for our student and professional programs for 2025-2026.
PQA’s Board of Directors represents a diverse group of thought leaders and experts in health care, who understand how medication optimization improves patient outcomes and supports a value-based care system. Their expertise helps PQA advance the safe and appropriate use of medicines. This blog is one in a series profiling PQA's Board members.
There are numerous opportunities for you to be part of the PQA Convening events in the coming months. Registration is also open for the 2024 PQA Leadership Summit and PQA Convenes: Quality Medication Use in Rare Disease. We also invite submissions for breakout session and poster abstract proposals for the 2025 PQA Annual Meeting, which is set to take place May 19-21 in Tampa, Fla.
Adherence to medications for cholesterol, hypertension, and diabetes helped Medicare beneficiaries avoid up to $29.2 billion in healthcare costs over six years (2016-21), according to the 2024 National Impact Assessment of CMS Quality Measures Report. This report underscores the importance of high-impact measures for chronic conditions, as evidence-based management efforts can significantly reduce complications and mortality.
PQA has issued an eight-point call to action for improving the quality and measurement of medication therapy management (MTM) services. The call was developed with extensive stakeholder input as part of a national, multi-phase initiative that PQA launched in 2023 to identify a pathway for new quality measures. It is the focus of a report published this month, “Advancing Medication Therapy Management Quality Measurement.”.
PQA has received a 2024 Power of Associations Gold Award from the American Society of Association Executives (ASAE) for the PQA Diverse Quality Leaders Program. The program helps individuals at various career stages become leaders in health care quality focused on safe, effective and appropriate medication use.
PQA provides healthcare quality experience to students from a wide variety of disciplines. This summer, we are hosting four students through our internship and MPH practicum programs.
Registration is open for the 2024 PQA Leadership Summit, November 7-8, 2024, in Arlington, Va., and PQA Convenes: Quality Medication Use in Rare Disease, which will take place before the summit on November 7. This year’s summit will focus on pharmacy measure use in value-based arrangements (VBAs) and quality improvement programs.
PQA published the Strategies to Expand Value-Based Pharmacist-Provided Care Action Guide five years ago. The guide was designed to spark conversation and foster collaboration between community pharmacy organizations, pharmacists and health care payers.
Through convening events, research, pilots and work to develop standard pharmacy quality measures, PQA has been a national leader in advancing pharmacist-provided care. A 2018 PQA-convened task force identified 15 strategies to expand value-based pharmacist-provided care, which form the centerpiece of the 2019 Strategies to Expand Value-Based Pharmacist-Provided Care Action Guide. The guide was designed to spark conversation and foster collaboration between community pharmacy organizations, pharmacists and health care payers.
Patients receiving specialty medications often have complex, high-cost treatment needs, necessitating close management from care teams, including specialty pharmacies. Recognizing this, specialty pharmacy stakeholders have articulated the need for standardized turnaround time (TAT) measurement and reporting to better understand a key aspect of specialty pharmacy quality.
The use of specialty medicine has grown rapidly in recent decades, fueling parallel growth in the number of specialty pharmacies that serve patients who are prescribed specialty medications. Patients receiving specialty medications often have complex, high-cost treatment needs, necessitating close management from care teams, including specialty pharmacies. Specialty pharmacies dispense medications, for which timely initiation of therapy is a clinical priority to optimize outcomes.
Diverse Voices in Quality is a PQA blog series that showcases the successful career paths and experiences of medication use quality professionals from diverse groups at PQA member organizations. A part of PQA’s Diverse Quality Leaders Program, this series celebrates the achievements of our members who reflect our nation’s diversity and provides everyone with insights and inspiration for becoming a leader in quality.
PQA, in partnership with Inovalon, is evaluating the impact of the Medicare out-of-pocket cost cap for insulin on persistence to basal insulin.
More than 400 leaders from PQA member organizations attended the 2024 PQA Annual Meeting, May 14-16, to network, engage and gain actionable insights.
Oral anticancer medications (OAMs) are a growing and important tool in the fight against cancer. More than 120 FDA-approved OAMs were used in clinical practice in 2022, and OAMs represent more than one-third of cancer medications in the development pipeline.
PQA members and health quality professionals gathered in Baltimore, Md., May 14-16, for the 2024 PQA Annual Meeting.
The 2024 PQA Annual Meeting poster session featured 23 quality improvement and research projects. Sponsored by Pharmacy Quality Solutions, the session provided an opportunity for authors to showcase their work and for attendees to engage in insightful dialogue about healthcare quality.
